Zynerba shares plunge as cannabis-based epilepsy gel fails study


Zynerba Pharmaceuticals Inc.'s stock lost more than half its value on Monday after the U.S. drug developer said its synthetic cannabis-based gel for epilepsy failed a mid-stage study.
Source link